Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC
Status:
Terminated
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),
a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small
cell lung cancer (NSCLC).